4//SEC Filing
Norry Elliot 4
Accession 0001104659-24-004523
CIK 0001621227other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 5:01 PM ET
Size
8.9 KB
Accession
0001104659-24-004523
Insider Transaction Report
Form 4
Norry Elliot
Chief Medical Officer
Transactions
- Award
Option to purchase Ordinary Shares
2024-01-15+2,544,432→ 2,544,432 totalExercise: $0.14Exp: 2034-01-15→ Ordinary Shares (2,544,432 underlying) - Award
Option to purchase Ordinary Shares
2024-01-15+565,416→ 565,416 totalExercise: $0.00→ Ordinary Shares (565,416 underlying)
Footnotes (5)
- [F1]The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.
- [F5]The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001798117
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 5:01 PM ET
- Size
- 8.9 KB